

Product Name	: Ponatinib
Synonyms	: AP 24534; AP24534; AP-24534
Cat No.	: M16756
CAS Number	: 943319-70-8
Molecular Formula	: C ₂₉ H ₂₇ F ₃ N ₆ O
Formula Weight	: 532.56
Chemical Name	: Benzamide, 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-
Description	Ponatinib (AP 24534) is a potent, orally active pan-inhibitor of BCR-ABL kinase with IC₅₀ of 0.37 and 2.0 nM for ABL and mutant ABLT315I, respectively; retains high potency against other ABL mutants Q252H, Y253F, M351T and H396P (IC₅₀s < 0.5 nM), also inhibits c-Src, Lyn, c-KIT, VEGFR2, FGFR1, PDGFRα (IC₅₀s = 0.2-5 nM); inhibits the growth of cells expressing native or mutant BCR-ABL (IC₅₀s = 0.5-36 nM) suppresses BCR-ABL(T315I)-driven tumor growth in mice, and completely abrogated resistance in cell-based mutagenesis screens. Blood Cancer Approved
Pathway	: Angiogenesis
Target	: Bcr-Abl
Receptor	: Abl; c-Kit; c-Src; FGFR1; PDGFRα; VEGFR2; LYN
Solubility	: DMSO: ≥ 50 mg/mL
SMILES	: CN1CCN(CC2=C(C=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2)C(F)(F)F)CC1
Storage	: (-20°C)
Stability	: ≥ 2 years
Reference	:

1. Gozgit JM, et al. Mol Cancer Ther. 2011 Jun;10(6):1028-35. | 2. Huang WS, et al. J Med Chem. 2010 Jun 24;53(12):4701-19. | 3. O'Hare T, et al. Cancer Cell. 2009 Nov 6;16(5):401-12. | 4. Gozgit JM, et al. Mol Cancer Ther. 2012 Mar;11(3):690-9.